GeekWire

MARCH 8, 2022

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We

Biotechnology 107

Biotechnology .Net Programming Company 107

GeekWire

NOVEMBER 30, 2022

Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. Adaptive Biotechnologies , Absci , and Zymeworks also announced layoffs this year. Sana CEO Steve Harr. Sana Photo). Seattle startup TwinStrand Biosciences also reportedly laid off staff.

Biotechnology 91

Biotechnology Company Programming Financial 91

GeekWire

JULY 15, 2021

Sana Biotechnology , a young and fast-growing Seattle-based biotech, has chosen the San Francisco Bay Area as the site for its new biomanufacturing facility. Competition for researchers skilled in biomanufacturing and other areas can be stiff, and the Bay Area is a much larger, more established biotechnology hub than Seattle.

Biotechnology 102

Biotechnology Development Construction Advertising 102

GeekWire

JANUARY 13, 2021

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has f iled to go public. And like many biotechnology companies it is losing money. Sana would become the latest in a string of Seattle area biotechnology companies to join the public ranks in recent months. stake in Sana.

Biotechnology 127

Biotechnology Applications .Net Company 127

GeekWire

MARCH 9, 2022

Adaptive Biotechnologies has a new CFO. Tycho Peterson, Adaptive’s new CFO. Morgan Chase Photo). Tycho Peterson comes from J.P. Morgan Chase, where he most recently served in its healthcare group as managing director, life science tools and diagnostics.

Biotechnology 92

Biotechnology Healthcare Open Source Sports 92

GeekWire

FEBRUARY 3, 2021

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).

Biotechnology 88

Biotechnology .Net Company Engineering 88

GeekWire

FEBRUARY 15, 2022

Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Adaptive moved into its new headquarters in September. Co-founders Harlan (left) and Chad Robins on the new plaza. GeekWire Photo / Charlotte Schubert). million in revenue last year, a 57% year-over-year increase.

Biotechnology 87

Biotechnology .Net Development Study 87

GeekWire

FEBRUARY 1, 2021

Adaptive Biotechnologies). Adaptive Biotechnologies has promoted one exec, while another is departing next month. Adaptive Biotechnologies’ EVP of Operations and Management Nancy Hill will depart the company in March. Bevier joined the F5 board in 2006. Mark Adams. Mark Adams is now COO.

Biotechnology 104

Biotechnology Fractional CTO CTO Hire Financial 104

GeekWire

JULY 14, 2020

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock — 6 million of its own, and 2 million from an investor — to help accelerate the company’s work.

Biotechnology 66

Biotechnology Development Microsoft Report 66

GeekWire

OCTOBER 19, 2021

Sana Biotechnology has a new $50 million tool in its toolbox. Sana CEO and president Steve Harr. Sana Photo). Sana signed an agreement with Beam Therapeutics for non-exclusive commercial rights to the Cambridge, Mass.-based based biotech’s gene editing system, called CRISPR-Cas12b.

Biotechnology 118

Biotechnology System Programming Engineering 118

GeekWire

NOVEMBER 10, 2020

Adaptive Biotechnologies CEO Chad Robins. Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19. GeekWire Photo). Adaptive posted revenue of $26.3 million, up 1% year-over-year, and earnings per share of -$0.27.

Biotechnology 69

Biotechnology Pharmaceuticals Development System 69

GeekWire

SEPTEMBER 21, 2021

Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. GeekWire Photos / Charlotte Schubert).

Biotechnology 98

Biotechnology Real Estate Analysis Research 98

GeekWire

SEPTEMBER 26, 2024

Nautilus Biotechnology Photo) — After more than two decades at scientific instruments company Agilent Technologies, Ken Suzuki is now chief marketing officer for Nautilus Biotechnology. ” Ken Suzuki. Seattle-based Nautilus has designed a platform for analyzing proteomes, a term for the proteins produced by an organism.

CTO 90

CTO Healthcare Biotechnology Nonprofit 90

TechSpot

JULY 24, 2024

The UK Space Agency and BiologIC Technologies are partnering to develop advanced biotechnologies, including vaccines and gene therapies, for space manufacturing.

Biotechnology 110

Biotechnology Research Development 110

GeekWire

OCTOBER 9, 2024

Other spinouts associated with the institute include Cyrus Biotechnology , Sana Biotechnology , A-Alpha Bio and Xaira Therapeutics. AstraZeneca paid $1.1 billion to acquire a different spinout, Icosavax , which develops synthetic vaccines that target naturally occurring viruses.

Biotechnology 140

Biotechnology Pharmaceuticals Artificial Intelligence Research 140

GeekWire

JULY 27, 2020

Chad Robins, CEO of Adaptive Biotechnologies, speaks at the site of the company’s future corporate headquarters in Seattle, standing in front of the final piece of structural steel before it’s put into place. Stephen Brashear/AP Images for Adaptive Biotechnologies). Stephen Brashear/AP Images for Adaptive Biotechnologies).

Biotechnology 102

Biotechnology Real Estate Industry Microsoft 102

GeekWire

SEPTEMBER 13, 2024

Sana Photo) — Sana Biotechnology CFO Nathan Hardy is stepping down, effective Oct. Investors include Seattle’s Voyager Capital, Fortson VC, Brighton Park Capital, CVC Growth Partners, Centana Growth Partners, and others. Other key personnel changes across the Pacific Northwest tech industry: Nathan Hardy.

Biotechnology 101

Biotechnology Industry Mobile Google 101

GeekWire

APRIL 15, 2021

Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo).

Biotechnology 88

Biotechnology Education Web Services Insurance 88

GeekWire

JUNE 11, 2024

LinkedIn Photos) Seattle startup Cyrus Biotechnology is spinning out a business that will expand access to the company’s software technology, with the potential of supporting innovation in drug development, agriculture, synthetic biology and manufacturing.

Software 109

Software Software Development Company 109

GeekWire

AUGUST 23, 2021

In the previous four years, Adaptive Biotechnologies was the only Washington state biotech company to go public. Sana Biotechnology, for instance, is led by Steve Harr , former CFO and corporate development head at Juno Therapeutics, a Seattle company that went public in 2014 and was later acquired by Celgene for $9 billion.

Biotechnology 125

Biotechnology Company Trends Software 125

GeekWire

JANUARY 14, 2022

The Bill & Melinda Gates Foundation has committed $40 million in equity investment and $10 million in grant funding to Vir Biotechnology for the development of therapies against HIV and Malaria, Vir announced Friday. government has been buying to fight Omicron.

Biotechnology 104

Biotechnology Government Research Development 104

GeekWire

APRIL 12, 2023

Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.

Biotechnology 98

Biotechnology Policies Energy Meeting 98

Gizmodo

JULY 14, 2021

An expert committee says heritable genome editing of humans is still too risky and that the World Health Organization should take on a leading role when it comes to regulating this emerging biotechnology. Read more.

Biotechnology 79

Biotechnology Engineering 79

GeekWire

JULY 8, 2021

Absci is the latest in a string of Washington state biotech startups to test the public markets — others including Impel Neuropharma, Sana Biotechnology, Athira Pharma, and Silverback Therapeutics have had IPOs in the past year. The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Alexandre.

Biotechnology 129

Biotechnology Industry Real Estate Company 129

GeekWire

JULY 29, 2021

The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Leslie Alexandre, CEO of Life Sciences Washington. Biotech IPOs reached an all-time high last year, according to Biopharma Dive , and the pace is continuing into 2021.

Biotechnology 138

Biotechnology Company Pharmaceuticals Research 138

GeekWire

JUNE 30, 2021

The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Three Washington state companies — Sana Biotechnology , Impel Neuropharma and Paymentus — have gone public with a traditional IPO this year.

Company 126

Company Biotechnology .Net Programming 126

GeekWire

AUGUST 11, 2021

So how do Washington state’s technology and biotechnology companies measure up? However, Adaptive Biotechnologies went public only two years ago, and it appears the rule does not apply for the first four to five years after an IPO. RELATED: The push for corporate board diversity is growing. Seemingly better.

Biotechnology 101

Biotechnology Company Meeting Nonprofit 101

Tech Republic Big Data

DECEMBER 26, 2016

As interesting as big data can be in Silicon Valley, its most fascinating applications often happen elsewhere.

Big Data 111

Big Data Biotechnology Data Applications 111

GeekWire

JULY 18, 2023

After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is now planning to merge with New York City-based Neurogene, a gene therapy startup.

Biotechnology 74

Biotechnology Company Development 74

GeekWire

DECEMBER 30, 2020

In June, Seattle biotechnology upstart Sana Biotechnology revealed that it had raised more than $700 million in venture funding. Which of these Washington state companies did NOT go public in 2020: Accolade, Adaptive Biotechnologies, Athira Pharma, Silverback Therapeutics? Adaptive Biotechnologies (It went public in 2019).

Biotechnology 131

Biotechnology Sports Microsoft Research 131

GeekWire

NOVEMBER 13, 2020

Adaptive Biotechnologies says it’s proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added to the evidence that its approach is more accurate than currently available antibody tests. Adaptive Biotechnologies Photo).

Biotechnology 136

Biotechnology Study Comparison .Net 136

GeekWire

JULY 2, 2020

OncoSenX is the spinoff of a third company, Seattle-based Oisin Biotechnologies. The researchers said they have selected the two most promising DNA sequences for further testing. Researchers at OncoSenX are using Fusogenix for cancer research on the treatment of solid tumors.

Research 144

Research Pharmaceuticals Biotechnology Development 144

GeekWire

NOVEMBER 19, 2020

Others include Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and more, in addition to work being done at Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Benaroya Research Institute, and others.

Biotechnology 142

Biotechnology Research CTO Development 142

GeekWire

OCTOBER 9, 2024

Susan Wyrick of Sana Biotechnology. LinkedIn Photo) — Susan Wyrick , senior vice president of finance and accounting at Sana Biotechnology , is serving as acting chief financial officer, treasurer, and principal accounting officer for the publicly traded company.

Biotechnology 86

Biotechnology Microsoft Dell Education 86

GeekWire

NOVEMBER 9, 2023

Adaptive Biotechnologies CEO Chad Robins speaks at the GeekWire Summit in 2019.

Biotechnology 86

Biotechnology Real Estate .Net Conference 86

GeekWire

MARCH 18, 2024

Clockwise, from top left: SEngine Precision CEO Carla Grandori; Joon Care CEO Emily Pesce; FlavorCloud CEO Rathna Sharad; AltPep CEO Valerie Daggett; and Strella Biotechnology CEO Katherine Sizov. Founded in 2017, Strella won GeekWire’s Elevator Pitch competition in 2022.

Company 83

Company Biotechnology Chemicals Survey 83

GeekWire

MAY 11, 2020

OncoSenX is a spinout out of Oisin Biotechnologies, a 5-year-old Seattle company also led by Scholz, a veteran biotech entrepreneur. The Seattle-based company just extended its oversubscribed SAFE (Simple Agreement for Future Equity) to allow for more capital, confirmed CEO Matthew Scholz. million to date.

Biotechnology 142

Biotechnology System Company 142